RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
Dynogen Pharma gets $50M round (TheDeal.com)
News | 04. 19. 2004
Dynogen Pharmaceuticals
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
